Holen Sie sich die Stockscreener-App
33.96
0.85%
-0.29
Handel nachbörslich:
33.96
Schlusskurs vom Vortag:
$34.25
Offen:
$34.05
24-Stunden-Volumen:
1.46M
Relative Volume:
0.71
Marktkapitalisierung:
$7.00B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$424.88M
KGV:
16.62
EPS:
2.0439
Netto-Cashflow:
$447.20M
1W Leistung:
-10.84%
1M Leistung:
-17.23%
6M Leistung:
-23.10%
1J Leistung:
-21.26%
1-Tages-Spanne:
$33.62
$34.23
1-Wochen-Bereich:
$33.17
$35.58
52-Wochen-Spanne:
$33.17
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
33.96 | 7.06B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
462.60 | 174.37B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.04 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.12 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.18 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
NTRA
Natera Inc
|
211.56 | 29.60B | 2.31B | -208.16M | 76.11M | -1.5366 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
QIAGEN NV Hits Day Low of $33.82 Amid Price Pressure - Markets Mojo
Primer: QIAGEN NV (QIA GY)May 2026 - Smartkarma
QIAGEN NV : Jefferies maintains a Buy rating - marketscreener.com
How The Qiagen (QGEN) Investment Story Is Shifting As Analysts Rework Their Assumptions - Yahoo Finance
Qiagen Trims 2026 Outlook After Mixed Q1 and QuantiFERON Weakness - TipRanks
Qiagen (NYSE:QGEN) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
QIAGEN N.V. (QGEN.US) will release its earnings report after the market closes on May 6. - Moomoo
Lower QuantiFERON demand leads QIAGEN (NYSE: QGEN) to trim 2026 outlook - Stock Titan
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $38 to $45 - Moomoo
MSN Money - MSN
Robert W. Baird Upgrades Qiagen (NYSE:QGEN) to Strong-Buy - MarketBeat
Morgan Stanley Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $39.69 - Moomoo
Qiagen Shares Plunge 10.7 Percent to Seven Year Low - HarianBasis.co
Pictet Asset Management Holding SA Reduces Holdings in Qiagen N.V. $QGEN - MarketBeat
Baird upgrades Qiagen NV (QGEN) - MSN
Qiagen Is Maintained at Overweight by JP Morgan - Moomoo
Barclays downgrades Qiagen NV (QGEN) - MSN
QGEN Maintained by JP Morgan -- Price Target Lowered to $45 - GuruFocus
QGEN Maintained by Citigroup -- Price Target Lowered to $38.00 - GuruFocus
JPMorgan Chase & Co. Has Lowered Expectations for Qiagen (NYSE:QGEN) Stock Price - MarketBeat
Citigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00 - MarketBeat
QGEN Maintained by Barclays -- Price Target Lowered to $38.00 - GuruFocus
Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight - GlobeNewswire Inc.
Citi Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $38 - Moomoo
QIAGEN NV Hits 52-Week Low at USD 33.82 Amidst Declining Performance - Markets Mojo
Morgan Stanley Cuts Price Target on QIAGEN to $40 From $51, Keeps Equalweight Rating - marketscreener.com
QGEN Upgraded by Baird -- Price Target Lowered to $43.00 - GuruFocus
Baird Upgrades QIAGEN to Outperform From Neutral, Cuts Price Target to $43 From $53 - marketscreener.com
Qiagen Sets Date for Publication of 2025 Annual Financial Report - The Globe and Mail
QIAGEN NV : DZ Bank gives a Buy rating - marketscreener.com
Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Qiagen (NYSE:QGEN) Sets New 12-Month LowShould You Sell? - MarketBeat
Qiagen N.V. (NYSE:QGEN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Qiagen NV (QGEN) Q1 2026 Earnings Call Highlights: Navigating Mi - GuruFocus
Baird upgrades Qiagen stock rating on valuation after pullback By Investing.com - Investing.com India
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $50 - Moomoo
Baird upgrades Qiagen stock rating on valuation after pullback - Investing.com
QIAGEN NV : Barclays reiterates its Neutral rating - marketscreener.com
Baird Upgrades Qiagen NV (QGEN) to Outperform - StreetInsider
Is Qiagen NV (QGEN) a Bargain After 10.7% Drop? GF Value Says Un - GuruFocus
Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1 - Yahoo Finance
Qiagen N.V. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Earnings Call Summary | Qiagen NV(QGEN.US) Q1 2026 Earnings Conference - Moomoo
QIAGEN NV : Jefferies keeps its Buy rating - marketscreener.com
Qiagen NV (QGEN) PT Lowered to $38 at Barclays - StreetInsider
Qiagen (NYSE:QGEN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
QIAGEN slides after cutting 2026 outlook, citing weaker QuantiFERON demand and cautious customer spending - Quiver Quantitative
German Shares Slip; Qiagen Tumbles on Outlook Downgrade - marketscreener.com
Qiagen N.V. 2026 Q1ResultsEarnings Call Presentation (NYSE:QGEN) 2026-04-28 - Seeking Alpha
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):